Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMD NASDAQ:MDXG NASDAQ:OM NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$15.59-2.6%$14.98$13.14▼$19.85$1.01B2.09788,962 shs510,801 shsMDXGMiMedx Group$6.72-0.3%$7.00$5.59▼$10.14$997.25M1.73608,545 shs591,485 shsOMOutset Medical$15.05-1.4%$14.06$5.85▼$25.35$271.29M2.13276,530 shs364,733 shsTNDMTandem Diabetes Care$14.96-2.8%$12.89$9.98▼$38.28$1.04B1.481.86 million shs1.26 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode0.00%+3.69%+8.91%+7.23%-10.71%MDXGMiMedx Group-0.15%+2.43%-3.99%-2.74%+18.25%OMOutset Medical-1.67%+14.13%+7.69%-21.45%+74.14%TNDMTandem Diabetes Care-0.97%+7.02%+22.43%-4.71%-54.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$15.59-2.6%$14.98$13.14▼$19.85$1.01B2.09788,962 shs510,801 shsMDXGMiMedx Group$6.72-0.3%$7.00$5.59▼$10.14$997.25M1.73608,545 shs591,485 shsOMOutset Medical$15.05-1.4%$14.06$5.85▼$25.35$271.29M2.13276,530 shs364,733 shsTNDMTandem Diabetes Care$14.96-2.8%$12.89$9.98▼$38.28$1.04B1.481.86 million shs1.26 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode0.00%+3.69%+8.91%+7.23%-10.71%MDXGMiMedx Group-0.15%+2.43%-3.99%-2.74%+18.25%OMOutset Medical-1.67%+14.13%+7.69%-21.45%+74.14%TNDMTandem Diabetes Care-0.97%+7.02%+22.43%-4.71%-54.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.00Hold$16.858.08% UpsideMDXGMiMedx Group 2.50Moderate Buy$12.0078.57% UpsideOMOutset Medical 2.50Moderate Buy$24.6763.90% UpsideTNDMTandem Diabetes Care 2.18Hold$21.1941.63% UpsideCurrent Analyst Ratings BreakdownLatest OM, TNDM, INMD, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$15.0010/15/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$14.00 ➝ $16.0010/10/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$14.00 ➝ $16.0010/10/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold10/8/2025INMDInModeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025MDXGMiMedx GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025OMOutset MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TNDMTandem Diabetes CareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$11.00 ➝ $15.009/29/2025INMDInModeZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/29/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M2.50$1.78 per share8.78$10.12 per share1.54MDXGMiMedx Group$348.88M2.85$0.33 per share20.34$1.31 per share5.13OMOutset Medical$113.69M2.35N/AN/A$7.49 per share2.01TNDMTandem Diabetes Care$940.20M1.08N/AN/A$4.01 per share3.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.476.318.57N/A44.50%18.38%16.35%11/5/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2122.4721.00N/A8.84%23.03%17.09%10/29/2025 (Estimated)OMOutset Medical-$127.98M-$20.290.00∞N/A-82.06%-97.17%-32.84%11/5/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/6/2025 (Estimated)Latest OM, TNDM, INMD, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025TNDMTandem Diabetes Care-$0.31N/AN/AN/A$235.80 millionN/A11/5/2025Q3 2025INMDInMode$0.32N/AN/AN/A$88.05 millionN/A11/5/2025Q3 2025OMOutset Medical-$0.64N/AN/AN/A$30.69 millionN/A10/29/2025Q3 2025MDXGMiMedx Group$0.07N/AN/AN/A$94.74 millionN/A8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A9.608.58MDXGMiMedx Group0.084.393.90OMOutset Medical0.637.476.05TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%MDXGMiMedx Group79.15%OMOutset MedicalN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINMDInMode6.92%MDXGMiMedx Group1.70%OMOutset Medical2.40%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableOMOutset Medical52017.77 million17.34 millionNot OptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableOM, TNDM, INMD, and MDXG HeadlinesRecent News About These CompaniesStephens Investment Management Group LLC Buys 30,854 Shares of Tandem Diabetes Care, Inc. $TNDMOctober 22 at 9:12 AM | marketbeat.comStifel Reiterates Tandem Diabetes Care (TNDM) Hold RecommendationOctober 22 at 4:08 AM | msn.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMOctober 21 at 7:20 PM | prnewswire.comTandem Diabetes Care (TNDM): Evaluating Valuation After Stifel Review and New Product LaunchesOctober 21 at 6:06 PM | finance.yahoo.comStifel Nicolaus Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)October 21 at 8:10 AM | marketbeat.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 20 at 7:03 PM | globenewswire.comTandem Diabetes Care (TNDM) Is Up 5.6% After Pump Correction Spurs Legal Scrutiny and Insider Buying – Has the Bull Case Changed?October 18, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDMOctober 18, 2025 | prnewswire.comTandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Hold at Wall Street ZenOctober 18, 2025 | marketbeat.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 17, 2025 | globenewswire.comTandem Diabetes Care (NASDAQ:TNDM) Shares Acquired Rep. Josh GottheimerOctober 17, 2025 | marketbeat.comBayforest Capital Ltd Has $173,000 Stock Position in Tandem Diabetes Care, Inc. $TNDMOctober 17, 2025 | marketbeat.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDMOctober 16, 2025 | businesswire.comBreaking Down Tandem Diabetes Care: 13 Analysts Share Their ViewsOctober 16, 2025 | benzinga.comTandem Diabetes Care Stock (TNDM) Opinions on FDA Clearance and Legal ConcernsOctober 16, 2025 | quiverquant.comQTNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law FirmOctober 16, 2025 | prnewswire.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMOctober 15, 2025 | prnewswire.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDMOctober 13, 2025 | prnewswire.comOngoing Securities Investigation into Tandem Diabetes Care, Inc. (TNDM) - Contact Levi & KorsinskyOctober 13, 2025 | theglobeandmail.comCiti Remains a Hold on Tandem Diabetes Care (TNDM)October 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDatavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 20253 Quantum Computing ETFs to Know—And Why 2 Don't Hold D-WaveBy Nathan Reiff | September 23, 2025Top 3 Dividend Achievers for October: High Yields, Growth AheadBy Thomas Hughes | October 1, 2025When Downgrades Create Opportunities: 3 Stocks to Watch NowBy Thomas Hughes | October 7, 2025Downgraded But Not Done: 3 Stocks Ready for a Market ComebackBy Thomas Hughes | September 24, 2025OM, TNDM, INMD, and MDXG Company DescriptionsInMode NASDAQ:INMD$15.59 -0.42 (-2.62%) Closing price 04:00 PM EasternExtended Trading$15.80 +0.22 (+1.38%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$6.72 -0.02 (-0.30%) Closing price 04:00 PM EasternExtended Trading$6.72 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Outset Medical NASDAQ:OM$15.05 -0.22 (-1.44%) Closing price 04:00 PM EasternExtended Trading$15.04 -0.01 (-0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Tandem Diabetes Care NASDAQ:TNDM$14.96 -0.43 (-2.79%) Closing price 04:00 PM EasternExtended Trading$14.98 +0.02 (+0.13%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
